+

WO2010079079A3 - Agents se liant au pdgf-rβ - Google Patents

Agents se liant au pdgf-rβ Download PDF

Info

Publication number
WO2010079079A3
WO2010079079A3 PCT/EP2009/067447 EP2009067447W WO2010079079A3 WO 2010079079 A3 WO2010079079 A3 WO 2010079079A3 EP 2009067447 W EP2009067447 W EP 2009067447W WO 2010079079 A3 WO2010079079 A3 WO 2010079079A3
Authority
WO
WIPO (PCT)
Prior art keywords
pdgf
imaging agents
binders
imaging
pdgfr
Prior art date
Application number
PCT/EP2009/067447
Other languages
English (en)
Other versions
WO2010079079A2 (fr
Inventor
Michael Ernest Marino
Faisal Ahmed Syud
Paul Schaffer
Brian Duh-Lan Lee
Rong Zhang
Malin Lindborg
Elin Gunneriusson
Christofer Lendel
Original Assignee
General Electric Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Company filed Critical General Electric Company
Priority to JP2011541452A priority Critical patent/JP2012512233A/ja
Priority to EP09795979A priority patent/EP2381966A2/fr
Priority to CN2009801572217A priority patent/CN102316903A/zh
Publication of WO2010079079A2 publication Critical patent/WO2010079079A2/fr
Publication of WO2010079079A3 publication Critical patent/WO2010079079A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Cette invention concerne des agents d'imagerie PDGF-Rβ qui sont des polypeptides marqués avec un générateur de signal (par exemple marqueur paramagnétique, isotope ou fluorophore), lesdits agents d'imagerie se liant spécifiquement au PDGF-Rβ. L'invention décrit également des procédés d'imagerie in vivo utilisant lesdits agents d'imagerie.
PCT/EP2009/067447 2008-12-17 2009-12-17 Agents se liant au pdgf-rβ WO2010079079A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2011541452A JP2012512233A (ja) 2008-12-17 2009-12-17 ＰＤＧＦ−Ｒβ結合剤
EP09795979A EP2381966A2 (fr) 2008-12-17 2009-12-17 Agents se liant au pdgf-r
CN2009801572217A CN102316903A (zh) 2008-12-17 2009-12-17 Pdgf-rbeta结合剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/336,780 US8124725B2 (en) 2007-12-19 2008-12-17 PDGF-Rβ binders
US12/336,780 2008-12-17

Publications (2)

Publication Number Publication Date
WO2010079079A2 WO2010079079A2 (fr) 2010-07-15
WO2010079079A3 true WO2010079079A3 (fr) 2010-12-16

Family

ID=42138890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/067447 WO2010079079A2 (fr) 2008-12-17 2009-12-17 Agents se liant au pdgf-rβ

Country Status (5)

Country Link
US (1) US8124725B2 (fr)
EP (1) EP2381966A2 (fr)
JP (1) JP2012512233A (fr)
CN (1) CN102316903A (fr)
WO (1) WO2010079079A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
EP2077272A1 (fr) * 2007-12-21 2009-07-08 Affibody AB Librairies de polypeptides avec une structure d'échafaudage prédéterminée
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (fr) * 2007-12-21 2009-06-24 Affibody AB Nouveaux polypeptides présentant une affinité de liaison pour HER2
EP2429593A2 (fr) * 2008-12-10 2012-03-21 Bergen Teknologioverføring AS Complexes biomoléculaires utilisés en tant qu'agents de contraste pour des procédés basés sur la tomographie à émission de positrons (pet) pour l'évaluation d'une fonction organique
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
JP6055417B2 (ja) * 2010-12-09 2016-12-27 ジーイー・ヘルスケア・リミテッド 放射性トレーサー組成物
KR20180042442A (ko) * 2010-12-22 2018-04-25 제너럴 일렉트릭 캄파니 방사성표지 ｈｅｒ２ 결합 펩티드
WO2013132094A1 (fr) * 2012-03-09 2013-09-12 Universitätsklinikum Heidelberg Ciblage à base de peptides du récepteur bêta du facteur de croissance dérivé des plaquettes (pdgfrβ) et du ligand cd276
CN102614536B (zh) * 2012-03-31 2013-01-30 南京市第一医院 细胞凋亡显像药物68Ga-NOTA-Duramycin及其制备方法
US9669403B2 (en) 2012-07-25 2017-06-06 Sony Corporation Microparticle measurement device and liquid delivery method in microparticle measurement device
WO2018219301A1 (fr) * 2017-05-31 2018-12-06 四川大学华西医院 VARIANT DE LIGAND INDUISANT L'APOPTOSE LIÉ AU FACTEUR DE NÉCROSE DE TUMEURS CIBLÉ PAR PDGFRβ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
CN111499762B (zh) * 2019-01-31 2022-04-26 四川大学华西医院 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077569A1 (fr) * 2007-12-19 2009-06-25 General Electric Company Biocinétique des polypeptides à élimination rapide
WO2009077175A1 (fr) * 2007-12-19 2009-06-25 Affibody Ab Polypeptide dérivé d'une protéine et se liant au pdgf
WO2009080811A1 (fr) * 2007-12-21 2009-07-02 Affibody Ab Banques de polypeptides présentant une structure prédéterminée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6673559B1 (en) * 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US6271364B1 (en) * 1999-02-23 2001-08-07 Amgen Inc. Analogs of NT-3
CA2298439A1 (fr) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Homologues de lipocaline
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1430136A1 (fr) * 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteines d'apolipoproteine d
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
RU2010116756A (ru) 2007-09-28 2011-11-10 Чугаи Сейяку Кабусики Кайся (Jp) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077569A1 (fr) * 2007-12-19 2009-06-25 General Electric Company Biocinétique des polypeptides à élimination rapide
WO2009077175A1 (fr) * 2007-12-19 2009-06-25 Affibody Ab Polypeptide dérivé d'une protéine et se liant au pdgf
WO2009080811A1 (fr) * 2007-12-21 2009-07-02 Affibody Ab Banques de polypeptides présentant une structure prédéterminée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOUGHTON P. J. ET AL.: "Imatinib Mesylate i a Potent Inhibitor of the ABCG" (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in vitro", CANCER RESEARCH, vol. 64, 1 April 2004 (2004-04-01), pages 2333 - 2337, XP002602202 *

Also Published As

Publication number Publication date
EP2381966A2 (fr) 2011-11-02
JP2012512233A (ja) 2012-05-31
WO2010079079A2 (fr) 2010-07-15
US8124725B2 (en) 2012-02-28
CN102316903A (zh) 2012-01-11
US20090191124A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2010079079A3 (fr) Agents se liant au pdgf-rβ
IL270930B (en) Oligosaccharide-protein conjugates
AP3856A (en) Improvements in feedwells.
AP2010005496A0 (en) Liner coupling pin.
GB2440870B (en) Automated payment system with additional capability
EP2383395A4 (fr) Système de fourniture d'informations de diagnostic pour machine de construction
EP2210268A4 (fr) Chimie novatrice utilisée dans des biocapteurs
EP1958140A4 (fr) Constitution d'equipes
HK1139624A1 (en) Composite magnetic cards
AP2010005424A0 (en) Assays.
HK1158309A1 (zh) 用於生物傳感器的新型 核-殼複合材料
HK1156368A1 (en) Methods for diagnosing ischemia
EP1932888A4 (fr) Colorant de marquage pour biomolecule, trousse de marquage et procede pour la detection de biomolecule
GB0805308D0 (en) Hybrid turntable
EP2201514A4 (fr) Paiement par poussée de fonds
HK1179181A1 (zh) 染料溶液
EP2215449A4 (fr) Essai de résistance d'une formation in situ
GB0523506D0 (en) Novel in vivo imaging compounds
GB0806980D0 (en) S.I.D (Suitcase information details)
EP2286226A4 (fr) Marqueurs sériques du diabète sucré de type ii
GB0822852D0 (en) Proxy-based payment system for portable ojects
EP2353156A4 (fr) Revêtement publicitaire d'intérieur de magasin pliant pour système de sécurité
AU321195S (en) Birdcage roof
HK1200823A1 (en) N-alkoxyamide conjugates as imaging agents n-
WO2009150139A3 (fr) Dérivés d’indolyl-pyridazinyl-diazabicyclononane sous forme marquée et non marquée et leur utilisation dans des procédés diagnostiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980157221.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09795979

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011541452

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009795979

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载